Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.

导出 OA

翻译打印收藏纠错

作者： Qi,Jin ^[1] ; Ethan,Harris ^[2] ; Jacquelyn A,Myers ^[3] ; Rashid,Mehmood ^[1] ; Anitria,Cotton ^[1] ; Hazheen K,Shirnekhi ^[4] ; David W,Baggett ^[4] ; Jeremy Qiang,Wen ^[1] ; Andrew B,Schild ^[1] ; Rahul S,Bhansali ^[5] ; Jonathon,Klein ^[6] ; Shilpa,Narina ^[6] ; Tim,Pieters ^[7] ; Akihide,Yoshimi ^[8] ; Shondra M,Pruett-Miller ^[6] ; Richard,Kriwacki ^[4] ; Omar,Abdel-Wahab ^[9] ; Sebastien,Malinge ^[10] ; Panagiotis,Ntziachristos ^[7] ; Esther A,Obeng ^[3] ; John D,Crispino ^[1]

作者单位： Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN. ^[1] Department of Medicine, The University of Chicago, Chicago, IL. ^[2] Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. ^[3] Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN. ^[4] Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA. ^[5] Center for Advanced Genome Engineering and the Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN. ^[6] Department of Biomolecular Medicine, Center for Medical Genetics and Cancer Research Institute, Ghent University, Ghent, Belgium. ^[7] Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. ^[8] Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY. ^[9] Translational Genomics in Leukemia, Cancer Centre, The Kids Research Institute Australia, Nedlands, WA, Australia. ^[10]